Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

Merck & Co’s Keytruda reigns supreme among immunotherapies ... making it the most frequent molecular alteration, and there are currently no effective targeted therapies directed against it ...